The US pharmaceutical trade association (PhRMA) asked CRA to identify concrete evidence-based proposals on market reforms aimed at creating a more competitive ‘off-patent’ sector in order to generate savings for the Italian National Health Services (SSN).
Working with industry participants, we assessed the potential policy alternatives based on an assessment of the economic and the political realities of the Italian market. This resulted in five potential policy options ranging from tougher enforcement of current generic policy to reforming the incentives for different distribution.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.